We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
26
Idexx Laboratories
IDXX
$44.6B
$48.9M 1.02%
76,587
+39
+0.1% +$23.7K
RMD icon
27
ResMed
RMD
$28.6B
$45.1M 0.94%
164,834
-968
-0.6% -$264K
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.21B
$45M 0.94%
2,775,997
– –
RLAY icon
29
Relay Therapeutics
RLAY
$4.23B
$43.6M 0.91%
8,345,610
+114,740
+1% +$438K
BHVN icon
30
Biohaven
BHVN
$2.25B
$42.1M 0.87%
2,802,853
– –
ABBV icon
31
AbbVie
ABBV
$448B
$39.6M 0.82%
170,870
+11,209
+7% +$2.28M
PEN icon
32
Penumbra
PEN
$12.5B
$37.2M 0.77%
146,895
-27,155
-16% -$6.85M
CI icon
33
Cigna
CI
$75.1B
$35.3M 0.73%
122,486
+11,774
+11% +$3.48M
GEHC icon
34
GE HealthCare
GEHC
$28.7B
$34.8M 0.72%
463,063
-52,405
-10% -$3.91M
ELV icon
35
Elevance Health
ELV
$83.3B
$33.9M 0.7%
104,971
+22,918
+28% +$7.13M
DHR icon
36
Danaher
DHR
$144B
$32.5M 0.68%
163,876
+27,065
+20% +$5.39M
LLY icon
37
Eli Lilly
LLY
$1.04T
$30.9M 0.64%
40,514
-406
-1% -$302K
WVE icon
38
Wave Life Sciences
WVE
$1.11B
$30M 0.62%
4,094,458
– –
MCK icon
39
McKesson
MCK
$97.8B
$29.3M 0.61%
37,957
-2,509
-6% -$1.77M
STE icon
40
Steris
STE
$21B
$29.2M 0.61%
118,112
+8,225
+7% +$1.97M
VEEV icon
41
Veeva Systems
VEEV
$32.4B
$29M 0.6%
97,506
-15,827
-14% -$4.45M
HCA icon
42
HCA Healthcare
HCA
$82B
$28M 0.58%
65,607
-33,515
-34% -$13M
ZBH icon
43
Zimmer Biomet
ZBH
$17.4B
$24.2M 0.5%
245,202
-22,514
-8% -$2.23M
COO icon
44
Cooper Companies
COO
$14B
$20M 0.42%
292,265
-63,809
-18% -$4.52M
HUM icon
45
Humana
HUM
$47.9B
$19.9M 0.41%
76,310
+27,186
+55% +$7.15M
GMED icon
46
Globus Medical
GMED
$10.4B
$18.7M 0.39%
326,867
-5,469
-2% -$315K
ALGN icon
47
Align Technology
ALGN
$12.6B
$18.1M 0.38%
144,676
-6,111
-4% -$957K
MOH icon
48
Molina Healthcare
MOH
$12B
$17.4M 0.36%
90,985
+16,963
+23% +$3.12M
HOLX
49
DELISTED
Hologic
HOLX
$16.7M 0.35%
247,886
– –
MGNX icon
50
MacroGenics
MGNX
$278M
$16.7M 0.35%
9,919,992
– –
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.